North Carolina
-
Pfizer broadens its RSV reach with deal for ReViral and its clinical-stage antivirals
Pfizer is already in the mix of companies pursuing vaccines for respiratory syncytial virus. The pharma giant is now broadening its scope with a deal to acquire ReViral Therapeutics, a biotech with two clinical-stage antivirals, each taking a different approach to stopping the potentially deadly pathogen.
-
Artificial Intelligence, BioPharma
Creyon Bio gets some green for a new take on AI and genetic meds R&D
Creyon Bio is the latest company to launch with artificial intelligence technology for drug R&D. The startup claims its technology can provide sufficient safety and toxicity data to enable a therapy to bypass the animal research currently needed before clinical trials.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
IQVIA report: Drug R&D reaches new highs, and not just for Covid-19 products
The biopharmaceutical industry continues to be a hotbed of activity, with more than 6,000 products in active development and a growing share of that innovation coming from new geographic regions. The findings are from a new industry report from IQVIA.
-
Regenerative med biotech ProKidney inks merger to get $825M for CKD cell therapy
ProKidney is going public in a SPAC merger that infuses the biotech with $825 million for Phase 3 tests and manufacturing of its autologous cell therapy for chronic kidney disease. More than slowing the decline in organ function, ProKidney says its cell therapy offers the potential to reverse injury caused by the condition.
-
Lawsuit: Mission Health purchase enabled HCA to create monopoly in North Carolina
A class-action lawsuit, filed by six North Carolina residents, alleges that HCA Healthcare bought Mission Health to gain monopolistic control in the Western part of the state, enabling it to drive up prices while lowering the quality of care.
-
Biotech startup using AI to take guesswork out of cancer drug selection raises $70M
Xilis is developing technology that creates a living model of a patient’s tumor, then applies artificial intelligence to determine the best drug or drug combinations to treat the cancer. Clinical trials are planned to test this precision medicine approach and the biotech startup has raised $70 million to fund its research.
-
CRO Parexel changes private equity hands again, this time for $8.5B
Four years after a private equity acquisition took Parexel private, the contract research organization is being acquired by two private equity firms for $8.5 billion. It’s the latest in a series of acquisitions to hit the CRO sector this year.
-
IQVIA adds to growing lab biz with $198M deal for Myriad contract services unit
IQVIA is paying nearly $200 million to purchase a Myriad Genetics subsidiary that provides pharmaceutical contract services, a deal that will put the new acquisition in the company’s Q2 Solutions unit. The deal follows IQVIA’s April announcement that it had secured full ownership of Q2, which had been a joint venture with Quest Diagnostics.
-
IQVIA pays Quest Diagnostics $760M to get full control of central lab joint venture
IQVIA has acquired Quest Diagnostics’ minority stake in Q2 Solutions, a central laboratory services joint venture the two companies formed in 2015. But Quest will remain a preferred provider of lab testing services under an agreement with Q2.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Regenerative medicine is already changing the way drugs are discovered and tested
Regenerative medicine might someday provide replacement organs for transplant patients. But Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine, explained how the technology is already helping in the discovery and testing of drugs.
-
BioPharma, Hospitals, Pharma, SYN
Humacyte sets out to bring regenerative medicine to Wall Street, then the world
Humacyte is going public via a SPAC merger that infuses it with $255 million for its regenerative medicine pipeline. The biotech’s technology produces universally implantable tissue that functions like human blood vessels.
-
If this self-sufficient hospital cannot stand alone, can any public hospital survive?
If Wilmington’s self-sufficient medical center cannot stand alone, can any public hospital avoid being subsumed into the large systems that economists say are helping propel the cost of American health care ever upward?
-
Chimerix starts Phase II/III trial of heparin-derived blood cancer drug in Covid-19
The development of the drug, DSTAT, is based on preclinical research indicating it can inhibit the inflammatory cytokines involved in the cytokine storms that cause much of the morbidity and mortality in Covid-19, as well as addressing the coagulation issues resulting in young patients having strokes.
-
LabCorp first to get FDA green light for Covid-19 at-home testing kit
The agency reissued the emergency use authorization that it gave to LabCorp last month for its RT-PCR test to allow for collection of samples at home by patients, with a doctor’s order.
-
Hospitals, Social Determinants
NC doctor says ER ‘like when the tide goes out before a tsunami’
After seeing their peers in Washington, and now New York, treat an onslaught of Covid-19 cases, hospitals in communities that haven’t been hit as hard yet are rushing to ready beds, ventilators and other needed equipment. MedCity News interviewed physicians across the U.S. to see how they are preparing for the next wave of the disease.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
